Frontiers in Cardiovascular Medicine (Jul 2022)
A Polygenic Risk Score Based on a Cardioembolic Stroke Multitrait Analysis Improves a Clinical Prediction Model for This Stroke Subtype
- Jara Cárcel-Márquez,
- Jara Cárcel-Márquez,
- Elena Muiño,
- Cristina Gallego-Fabrega,
- Cristina Gallego-Fabrega,
- Natalia Cullell,
- Natalia Cullell,
- Miquel Lledós,
- Laia Llucià-Carol,
- Laia Llucià-Carol,
- Tomás Sobrino,
- Francisco Campos,
- José Castillo,
- Marimar Freijo,
- Juan Francisco Arenillas,
- Victor Obach,
- José Álvarez-Sabín,
- Carlos A. Molina,
- Marc Ribó,
- Jordi Jiménez-Conde,
- Jaume Roquer,
- Lucia Muñoz-Narbona,
- Elena Lopez-Cancio,
- Mònica Millán,
- Rosa Diaz-Navarro,
- Cristòfol Vives-Bauza,
- Gemma Serrano-Heras,
- Tomás Segura,
- Laura Ibañez,
- Laura Heitsch,
- Laura Heitsch,
- Pilar Delgado,
- Rajat Dhar,
- Jerzy Krupinski,
- Raquel Delgado-Mederos,
- Luis Prats-Sánchez,
- Pol Camps-Renom,
- Natalia Blay,
- Lauro Sumoy,
- Rafael de Cid,
- Joan Montaner,
- Carlos Cruchaga,
- Carlos Cruchaga,
- Jin-Moo Lee,
- Joan Martí-Fàbregas,
- Israel Férnandez-Cadenas
Affiliations
- Jara Cárcel-Márquez
- Stroke Pharmacogenomics and Genetics Group, Institut d'Investigació Biomèdica Sant Pau (IIB SANT PAU), Barcelona, Spain
- Jara Cárcel-Márquez
- Departament de Medicina, Universitat Autònoma de Barcelona, Barcelona, Spain
- Elena Muiño
- Stroke Pharmacogenomics and Genetics Group, Institut d'Investigació Biomèdica Sant Pau (IIB SANT PAU), Barcelona, Spain
- Cristina Gallego-Fabrega
- Stroke Pharmacogenomics and Genetics Group, Institut d'Investigació Biomèdica Sant Pau (IIB SANT PAU), Barcelona, Spain
- Cristina Gallego-Fabrega
- Stroke Unit, Department of Neurology, Hospital de la Santa Creu i Sant Pau, Barcelona, Spain
- Natalia Cullell
- Stroke Pharmacogenomics and Genetics Group, Institut d'Investigació Biomèdica Sant Pau (IIB SANT PAU), Barcelona, Spain
- Natalia Cullell
- Stroke Pharmacogenomics and Genetics Laboratory, Fundación Docència i Recerca Mútua Terrassa, Hospital Mútua Terrassa, Terrassa, Spain
- Miquel Lledós
- Stroke Pharmacogenomics and Genetics Group, Institut d'Investigació Biomèdica Sant Pau (IIB SANT PAU), Barcelona, Spain
- Laia Llucià-Carol
- Stroke Pharmacogenomics and Genetics Group, Institut d'Investigació Biomèdica Sant Pau (IIB SANT PAU), Barcelona, Spain
- Laia Llucià-Carol
- Department de Genética i de Microbiologia, Universitat Autónoma de Barcelona, Barcelona, Spain
- Tomás Sobrino
- Clinical Neurosciences Research Laboratory, Hospital Clínico Universitario de Santiago de Compostela, Health Research Institute of Santiago de Compostela (IDIS), Santiago de Compostela, Spain
- Francisco Campos
- Clinical Neurosciences Research Laboratory, Hospital Clínico Universitario de Santiago de Compostela, Health Research Institute of Santiago de Compostela (IDIS), Santiago de Compostela, Spain
- José Castillo
- Clinical Neurosciences Research Laboratory, Hospital Clínico Universitario de Santiago de Compostela, Health Research Institute of Santiago de Compostela (IDIS), Santiago de Compostela, Spain
- Marimar Freijo
- Department of Neurology, Biocruces-Bizkaia Health Research Institute, Bilbao, Spain
- Juan Francisco Arenillas
- Stroke Unit, Department of Neurology, University Hospital of Valladolid, Valladolid, Spain
- Victor Obach
- Department of Neurology, Hospital Clínic de Barcelona, IDIBAPS, Barcelona, Spain
- José Álvarez-Sabín
- 0Stroke Unit, Department of Neurology, Hospital Universitari Vall d'Hebron, Barcelona, Spain
- Carlos A. Molina
- 0Stroke Unit, Department of Neurology, Hospital Universitari Vall d'Hebron, Barcelona, Spain
- Marc Ribó
- 0Stroke Unit, Department of Neurology, Hospital Universitari Vall d'Hebron, Barcelona, Spain
- Jordi Jiménez-Conde
- 1Department of Neurology, IMIM-Hospital del Mar; Neurovascular Research Group, IMIM (Institut Hospital del Mar d'Investigacions Mèdiques), Universitat Autònoma de Barcelona/DCEXS-Universitat Pompeu Fabra, Barcelona, Spain
- Jaume Roquer
- 1Department of Neurology, IMIM-Hospital del Mar; Neurovascular Research Group, IMIM (Institut Hospital del Mar d'Investigacions Mèdiques), Universitat Autònoma de Barcelona/DCEXS-Universitat Pompeu Fabra, Barcelona, Spain
- Lucia Muñoz-Narbona
- 2Department of Neurosciences, Hospital Germans Trias i Pujol, Universitat Autònoma de Barcelona, Barcelona, Spain
- Elena Lopez-Cancio
- 3Department of Neurology, University Hospital Central de Asturias (HUCA).Oviedo, Spain
- Mònica Millán
- 2Department of Neurosciences, Hospital Germans Trias i Pujol, Universitat Autònoma de Barcelona, Barcelona, Spain
- Rosa Diaz-Navarro
- 4Department of Neurology, Son Espases University Hospital, Illes Balears Health Research Institute (IdISBa), Palma, Spain
- Cristòfol Vives-Bauza
- 4Department of Neurology, Son Espases University Hospital, Illes Balears Health Research Institute (IdISBa), Palma, Spain
- Gemma Serrano-Heras
- 5Department of Neurology, University Hospital of Albacete, Albacete, Spain
- Tomás Segura
- 5Department of Neurology, University Hospital of Albacete, Albacete, Spain
- Laura Ibañez
- 6Department of Psychiatry, Washington University School of Medicine, Saint Louis, MO, United States
- Laura Heitsch
- 7Department of Emergency Medicine, Washington University School of Medicine, Saint Louis, MO, United States
- Laura Heitsch
- 8Department of Neurology, Washington University School of Medicine, Saint Louis, MO, United States
- Pilar Delgado
- 9Neurovascular Research Laboratory, Vall d'Hebron Institute of Research, Universitat Autònoma de Barcelona, Barcelona, Spain
- Rajat Dhar
- 8Department of Neurology, Washington University School of Medicine, Saint Louis, MO, United States
- Jerzy Krupinski
- 0Neurology Service, Hospital Universitari Mútua Terrassa, Terrassa, Spain
- Raquel Delgado-Mederos
- Stroke Unit, Department of Neurology, Hospital de la Santa Creu i Sant Pau, Barcelona, Spain
- Luis Prats-Sánchez
- Stroke Unit, Department of Neurology, Hospital de la Santa Creu i Sant Pau, Barcelona, Spain
- Pol Camps-Renom
- Stroke Unit, Department of Neurology, Hospital de la Santa Creu i Sant Pau, Barcelona, Spain
- Natalia Blay
- 1GenomesForLife-GCAT Lab, Germans Trias i Pujol Research Institute (IGTP), Badalona, Spain
- Lauro Sumoy
- 2High Content Genomics and Bioinformatics Unit, Germans Trias i Pujol Research Institute (IGTP), Badalona, Spain
- Rafael de Cid
- 1GenomesForLife-GCAT Lab, Germans Trias i Pujol Research Institute (IGTP), Badalona, Spain
- Joan Montaner
- 3Institute de Biomedicine of Seville, IBiS/Hospital Universitario Virgen del Rocío/CSIC/University of Seville and Department of Neurology, Hospital Universitario Virgen Macarena, Seville, Spain
- Carlos Cruchaga
- 6Department of Psychiatry, Washington University School of Medicine, Saint Louis, MO, United States
- Carlos Cruchaga
- 4Neurogenomics and Informatics Center at Washington University in St. Louis, Saint Louis, MO, United States
- Jin-Moo Lee
- 8Department of Neurology, Washington University School of Medicine, Saint Louis, MO, United States
- Joan Martí-Fàbregas
- Stroke Unit, Department of Neurology, Hospital de la Santa Creu i Sant Pau, Barcelona, Spain
- Israel Férnandez-Cadenas
- Stroke Pharmacogenomics and Genetics Group, Institut d'Investigació Biomèdica Sant Pau (IIB SANT PAU), Barcelona, Spain
- DOI
- https://doi.org/10.3389/fcvm.2022.940696
- Journal volume & issue
-
Vol. 9
Abstract
BackgroundOccult atrial fibrillation (AF) is one of the major causes of embolic stroke of undetermined source (ESUS). Knowing the underlying etiology of an ESUS will reduce stroke recurrence and/or unnecessary use of anticoagulants. Understanding cardioembolic strokes (CES), whose main cause is AF, will provide tools to select patients who would benefit from anticoagulants among those with ESUS or AF. We aimed to discover novel loci associated with CES and create a polygenetic risk score (PRS) for a more efficient CES risk stratification.MethodsMultitrait analysis of GWAS (MTAG) was performed with MEGASTROKE-CES cohort (n = 362,661) and AF cohort (n = 1,030,836). We considered significant variants and replicated those variants with MTAG p-value < 5 × 10−8 influencing both traits (GWAS-pairwise) with a p-value < 0.05 in the original GWAS and in an independent cohort (n = 9,105). The PRS was created with PRSice-2 and evaluated in the independent cohort.ResultsWe found and replicated eleven loci associated with CES. Eight were novel loci. Seven of them had been previously associated with AF, namely, CAV1, ESR2, GORAB, IGF1R, NEURL1, WIPF1, and ZEB2. KIAA1755 locus had never been associated with CES/AF, leading its index variant to a missense change (R1045W). The PRS generated has been significantly associated with CES improving discrimination and patient reclassification of a model with age, sex, and hypertension.ConclusionThe loci found significantly associated with CES in the MTAG, together with the creation of a PRS that improves the predictive clinical models of CES, might help guide future clinical trials of anticoagulant therapy in patients with ESUS or AF.
Keywords